

Frataxin Mitochondrial - Pipeline Review, H1 2020

<https://marketpublishers.com/r/F67400BA7806EN.html>

Date: February 2020

Pages: 55

Price: US\$ 3,500.00 (Single User License)

ID: F67400BA7806EN

Abstracts

Frataxin Mitochondrial - Pipeline Review, H1 2020

SUMMARY

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Frataxin Mitochondrial - Pipeline Review, H1 2020, outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe²⁺ to proteins involved in these pathways. It plays a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe²⁺ to Fe³⁺. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 6 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Friedreich Ataxia and Cardiomyopathy.

Furthermore, this report also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)

The report reviews Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Overview

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Companies
Involved in Therapeutics Development

AavantiBio Inc

Adverum Biotechnologies Inc

Biointaxis SL

Chondrial Therapeutics LLC

Design Therapeutics Inc

Fratagene Therapeutics Srl

Fulcrum Therapeutics Inc

Jupiter Orphan Therapeutics Inc

Panorama Research Inc

Pfizer Inc

PTC Therapeutics Inc

Voyager Therapeutics Inc

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Drug Profiles
ADVM-063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTI-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etravirine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate FXN for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JOT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTC-FA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Frataxin for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Activate Frataxin for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYFXN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Dormant Products

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Product Development Milestones

Featured News & Press Releases

Jan 13, 2020: MDA awards venture philanthropy funding of more than \$1M to AavantiBio to develop gene-targeting therapy for Friedreich's Ataxia

Dec 18, 2019: Chondrial Therapeutics announces dosing of first patients in phase 1 clinical program of CTI-1601 for treatment of Friedreich's ataxia and CTI-1601 granted rare pediatric disease designation and fast track designation by U.S. FDA

Nov 30, 2019: GoFAR partners with AavantiBio to advance gene therapy for Friedreich's Ataxia

Nov 30, 2019: GoFAR partners with AavantiBio to advance gene therapy for Friedreich's Ataxia

May 18, 2018: Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting

Oct 31, 2017: Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia

Aug 22, 2017: Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia

Aug 03, 2017: Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia

Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia

Feb 18, 2016: Agilis Biotherapeutics and Waisman Biomanufacturing enter into exclusive manufacturing agreement for Friedreich's Ataxia gene therapy

Aug 05, 2015: Key Patent Granted For AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia

Appendix

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AavantiBio Inc, H1 2020
Pipeline by Adverum Biotechnologies Inc, H1 2020
Pipeline by Biointaxis SL, H1 2020
Pipeline by Chondrial Therapeutics LLC, H1 2020
Pipeline by Design Therapeutics Inc, H1 2020
Pipeline by Fratagene Therapeutics Srl, H1 2020
Pipeline by Fulcrum Therapeutics Inc, H1 2020
Pipeline by Jupiter Orphan Therapeutics Inc, H1 2020
Pipeline by Panorama Research Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by PTC Therapeutics Inc, H1 2020
Pipeline by Voyager Therapeutics Inc, H1 2020
Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

AavantiBio Inc
Adverum Biotechnologies Inc
Biointaxis SL
Chondrial Therapeutics LLC
Design Therapeutics Inc
Fratagene Therapeutics Srl
Fulcrum Therapeutics Inc
Jupiter Orphan Therapeutics Inc
Panorama Research Inc
Pfizer Inc
PTC Therapeutics Inc
Voyager Therapeutics Inc

I would like to order

Product name: Frataxin Mitochondrial - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/F67400BA7806EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F67400BA7806EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970